Signals from SABR-COMET time to move on to phase III studies.
作者信息
Milano Michael T, Chowdhry Amit K, Salama Joseph K, Chmura Steven J
机构信息
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA.
Department of Radiation Oncology, Duke University, Durham, NC, USA.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S316. doi: 10.21037/atm.2019.09.152.
Abstract
摘要
相似文献
1
Signals from SABR-COMET time to move on to phase III studies.
Ann Transl Med. 2019 Dec;7(Suppl 8):S316. doi: 10.21037/atm.2019.09.152.
2
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
BMC Cancer. 2019 Aug 19;19(1):816. doi: 10.1186/s12885-019-5977-6.
3
Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial.
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):943-947. doi: 10.1016/j.ijrobp.2019.08.041. Epub 2019 Aug 27.
4
Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial.
BMC Cancer. 2019 Mar 28;19(1):275. doi: 10.1186/s12885-019-5461-3.
5
Stereotactic ablative body radiotherapy for lung cancer.
Clin Oncol (R Coll Radiol). 2015 May;27(5):280-9. doi: 10.1016/j.clon.2015.01.006. Epub 2015 Mar 4.
6
Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age.
Thorac Cancer. 2019 Jun;10(6):1489-1499. doi: 10.1111/1759-7714.13103. Epub 2019 May 23.
7
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Lancet Oncol. 2019 Apr;20(4):494-503. doi: 10.1016/S1470-2045(18)30896-9. Epub 2019 Feb 12.
8
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.
9
A Phase 2 Clinical Trial of SABR Followed by Immediate Vertebroplasty for Spine Metastases.
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):83-89. doi: 10.1016/j.ijrobp.2019.01.072. Epub 2019 Jan 23.
10
Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data.
Ann Transl Med. 2015 Jul;3(11):149. doi: 10.3978/j.issn.2305-5839.2015.06.15.
引用本文的文献
1
Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy.
Cancer Imaging. 2023 Mar 17;23(1):27. doi: 10.1186/s40644-023-00543-0.
2
Metastasis-directed therapy for oligometastasis and beyond.
Br J Cancer. 2021 Jan;124(1):136-141. doi: 10.1038/s41416-020-01128-5. Epub 2020 Nov 18.
本文引用的文献
1
The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond.
Front Oncol. 2019 Aug 2;9:706. doi: 10.3389/fonc.2019.00706. eCollection 2019.
2
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
BMC Cancer. 2019 Aug 19;19(1):816. doi: 10.1186/s12885-019-5977-6.
3
Integration of radiotherapy and immunotherapy for treatment of oligometastases.
Lancet Oncol. 2019 Aug;20(8):e434-e442. doi: 10.1016/S1470-2045(19)30157-3. Epub 2019 Jul 29.
4
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.
JAMA Oncol. 2019 Sep 1;5(9):1283-1290. doi: 10.1001/jamaoncol.2019.1449.
5
A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead?
Front Oncol. 2019 Jun 21;9:543. doi: 10.3389/fonc.2019.00543. eCollection 2019.
6
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
J Clin Oncol. 2019 Jun 20;37(18):1558-1565. doi: 10.1200/JCO.19.00201. Epub 2019 May 8.
7
Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years.
Front Oncol. 2019 Feb 27;9:111. doi: 10.3389/fonc.2019.00111. eCollection 2019.
8
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment.
Front Immunol. 2019 Feb 15;10:193. doi: 10.3389/fimmu.2019.00193. eCollection 2019.
9
Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade.
Radiother Oncol. 2019 Feb;131:45-51. doi: 10.1016/j.radonc.2018.11.022. Epub 2018 Dec 28.
10
The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment.
J Clin Oncol. 2018 Nov 10;36(32):3240-3250. doi: 10.1200/JCO.18.00847. Epub 2018 Sep 27.
Zotero 插件